NCT02420977CompletedEarly phase 1
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Source: ClinicalTrials.gov · Last updated 19 Mar 2025
Brief summary (registry, in English)
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 15 Apr 2015
- Start date
- 6 Dec 2018
- Primary completion date
- 1 Mar 2024
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Diseases
- Prostate cancer
- NCT number
- NCT02420977
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 23
- From 6 Dec 2018 to the primary completion date, 1 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior pelvic external beam radiation therapy or brachytherapy
- Hormone deprivation therapy
- Investigational therapy for prostate cancer
Other illness
- Chemotherapy for prostate cancer
Other
- Hemorrhagic cystitis or active prostatitis
Who the study is looking for
- Men 18 years of age or greater with recently diagnosed prostate cancer with planned radiation and ADT.
- Key inclusion criteria (the entire list of inclusion and exclusion criteria will appear later in section 4 of the protocol)
- Newly diagnosed prostate cancer pathologically proven by prostate biopsy
- Prostate biopsy histology grade ≥ Gleason 8-10
- Patients considered as candidates for and medically fit to undergo radiation and ADT
- At least 10 days after most recent prostate biopsy
Age in the registry: 18 years to 100 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Curtiland Deville Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.